Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial
This study will assess the efficacy of external beam radiotherapy, a robust alternative to surgery in muscle-invasive bladder cancer. Radiotherapy will be administered 5 d a week for 4 wk. It will be associated with a "radiosensitizer," an intravenous or oral drug, during the radiotherapy treatment. The study will measure the proportion of patients remaining recurrence free at 6 mo and thereafter. It will also evaluate the safety of the treatment and its impact on quality of life.PMID:38556413 | DOI:10.1016/j.euo.2024.03.008
Source: Cancer Control - Category: Cancer & Oncology Authors: V érane Achard B éatrice Fournier David D'Haese Joanna Krzystyniak Bertrand Tombal Morgan Roupret Paul Sargos Piet Dirix Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | External Beam Therapy | Oral Cancer | Study